rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Ramiro Sanchez

Director

Company insider

Files Form 4 as: Director, Rapport Therapeutics; Director, Alto Neuroscience; Chief Medical Officer, Cerevel Therapeutics Holdings.

Every Form 4 they filed

In numbers

Trades disclosed
31
Buys
0
Sells
4
Bought
$0
Sold
$1.6M
Companies
3
Companies where not an officer
2
First trade
28 Oct 2020
Last trade
10 Jun 2026
Last filed
10 Jun 2026

Companies traded

Where they are an officer
Cerevel Therapeutics HoldingsOfficer · last 1 Aug 20240 buys · 4 sells
Everywhere else they filed: board seats, 10% stakes, other companies
RAPP Rapport TherapeuticsDirector · Biotechnology · last 10 Jun 20260 buys · 0 sells
ANRO Alto NeuroscienceDirector · Biotechnology · last 12 May 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
10 Jun 2026filed 10 Jun 2026RAPP Rapport Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—15,200 at $0.00filing
10 Jun 2026filed 10 Jun 2026RAPP Rapport Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—15,200 at $0.00filing
12 May 2026filed 14 May 2026ANRO Alto Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code A—10,958 at $0.00filing
12 May 2026filed 14 May 2026ANRO Alto Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code A—10,958 at $0.00filing
2 Jan 2026filed 6 Jan 2026ANRO Alto Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code A$45K3,806 at $11.82filing
2 Jan 2026filed 6 Jan 2026ANRO Alto Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code A$45K3,806 at $11.82filing
12 Aug 2025filed 14 Aug 2025ANRO Alto Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code A—30,574 at $0.00filing
12 Aug 2025filed 14 Aug 2025ANRO Alto Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code A$8,6813,928 at $2.21filing
17 Jun 2025filed 18 Jun 2025RAPP Rapport Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—10,925 at $0.00filing
7 Nov 2024filed 7 Nov 2024RAPP Rapport Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—29,756 at $0.00filing
1 Aug 2024filed 5 Aug 2024Cerevel Therapeutics Holdingsoption or derivativeSEC FORM 4 Code D—1,393,153filing
1 Aug 2024filed 5 Aug 2024Cerevel Therapeutics Holdingsoption or derivativeSEC FORM 4 Code D—87,573 at $0.00filing
1 Aug 2024filed 5 Aug 2024Cerevel Therapeutics HoldingsSEC FORM 4 Code D—14,673filing
19 Jan 2024filed 23 Jan 2024Cerevel Therapeutics Holdingsoption or derivativeSEC FORM 4 Code A—87,573 at $0.00filing
26 Dec 2023filed 28 Dec 2023Cerevel Therapeutics Holdingsoption or derivativeSEC FORM 4 Code M—10,000 at $0.00filing
26 Dec 2023filed 28 Dec 2023Cerevel Therapeutics HoldingsSEC FORM 4 Code M$35K10,000 at $3.50filing
26 Dec 2023filed 28 Dec 2023Cerevel Therapeutics HoldingsSEC FORM 4 Sold$425K10,000 at $42.47filing
20 Dec 2023filed 21 Dec 2023Cerevel Therapeutics HoldingsSEC FORM 4 Sold$420K10,152 at $41.42filing
19 Dec 2023filed 21 Dec 2023Cerevel Therapeutics Holdingsoption or derivativeSEC FORM 4 Code M—24,825 at $0.00filing
19 Dec 2023filed 21 Dec 2023Cerevel Therapeutics HoldingsSEC FORM 4 Code M—24,825filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed4

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.